ROOT, Schweiz–(BUSINESS WIRE)–Wie Novocure (NASDAQ: NVCR) heute mitteilte, hat die U.S. Food and Drug Administration (FDA) Optune Lua für die gleichzeitige Anwendung mit PD-1/PD-L1-Inhibitoren oder Docetaxel zur Behandlung von erwachsenen Patient:innen mit metastasierendem nicht-kleinzelligem Lungenkarzinom zugelassen, deren Erkrankung unter oder nach einer platinbasierten Therapie fortgeschritten ist. „Novocure verfolgt das Ziel, das Überleben bei einigen der aggressivsten und am schwersten

The Biden administration’s latest executive order on expanding or protecting access to reproductive care could not only send more consumers to buy OTC contraceptives but also more voters to the polls

      

GSK plc announced it is investing £50 million into a major new five─year collaboration with the University of Cambridge and Cambridge University Hospitals, to accelerate research and development into immune─related

There’s no disguising the fact that there’s a great deal of demand for Intuitive Surgical’s Dv5 platform. Executives from the Sunnyvale, CA-based company spoke about the hot demand for the fifth iteration of the da Vinci surgical platform, which received a nod from FDA in March.

Immunotherapy and precision medicine show promise in better fighting cancer. What else does the research tell us? 

Astellas nabs class-first FDA approval for CLDN18.2 gastric cancer med Vyloy
fkansteiner
Fri, 10/18/2024 – 15:21

ACS Meeting News: Catalytic process creates butanol as a better biofuel option for gasoline

ACS Meeting News: Catalytic process creates butanol as a better biofuel option for gasoline

ACS Meeting News: Catalytic process creates butanol as a better biofuel option for gasoline

ACS Meeting News: Catalytic process creates butanol as a better biofuel option for gasoline